Rare diseases social epidemiology: analysis of inequalities
- PMID: 20824449
- DOI: 10.1007/978-90-481-9485-8_14
Rare diseases social epidemiology: analysis of inequalities
Abstract
Rare disease patients experience particular obstacles in accessing high quality healthcare. These obstacles include but are not limited to: (i) lack of scientific knowledge of their disease, (ii) lack of access to correct diagnosis, (iii) delays in diagnosis, (iv) lack of appropriate multidisciplinary healthcare, (v) lack of quality information and support at the time of diagnosis, (vi) undue social consequences, (vii) inequities and difficulties in access to treatment, rehabilitation and care, (viii) dissatisfaction with and loss of confidence in medical and social services, (ix) denied treatment by health professionals and (x) lack of availability of orphan drugs. Three surveys and their subsequent analysis, conducted by the European Organisation for Rare Diseases (EURORDIS), a non-governmental patient driven alliance of European patient organisations, demonstrate several of these obstacles by describing the experience of rare disease patients across 18 rare diseases and over 24 European countries as well as highlighting inequalities that exist between them.
Similar articles
-
A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.J Public Health Policy. 2010 Dec;31(4):407-20; discussion 420-1. doi: 10.1057/jphp.2010.30. J Public Health Policy. 2010. PMID: 21119648
-
Drugs for rare diseases: mixed assessment in Europe.Prescrire Int. 2007 Feb;16(87):36-42. Prescrire Int. 2007. PMID: 17323539
-
Access to information supporting availability of medicines for patients suffering from rare diseases looking for possible treatments: the EuOrphan Service.Medicina (Kaunas). 2007;43(6):441-6. Medicina (Kaunas). 2007. PMID: 17637514 Review.
-
[Orphan drugs--medications for patients with rare diseases].Ugeskr Laeger. 2006 Jun 5;168(23):2236-8. Ugeskr Laeger. 2006. PMID: 16768975 Danish.
-
Legal assessment of current situation on orphan patients in Lithuania.Medicina (Kaunas). 2008;44(8):571-6. Medicina (Kaunas). 2008. PMID: 18791333 Review.
Cited by
-
Are we forgetting to carry out serum protein electrophoresis as part of diagnosis workup?BMC Gastroenterol. 2022 Sep 4;22(1):406. doi: 10.1186/s12876-022-02477-6. BMC Gastroenterol. 2022. PMID: 36058908 Free PMC article.
-
Etiology unknown: Qualitative analysis of patient attributions of causality in scleroderma.J Scleroderma Relat Disord. 2018 Jun;3(2):182-188. doi: 10.1177/2397198318761480. Epub 2018 Mar 19. J Scleroderma Relat Disord. 2018. PMID: 35382239 Free PMC article.
-
[Identification of rare diseases in the oral cavity].Internist (Berl). 2018 Sep;59(9):972-980. doi: 10.1007/s00108-018-0464-8. Internist (Berl). 2018. PMID: 29974133 Review. German.
-
Time to diagnosis and determinants of diagnostic delays of people living with a rare disease: results of a Rare Barometer retrospective patient survey.Eur J Hum Genet. 2024 Sep;32(9):1116-1126. doi: 10.1038/s41431-024-01604-z. Epub 2024 May 16. Eur J Hum Genet. 2024. PMID: 38755315 Free PMC article.
-
Impact of social determinants of health on individuals living with generalized myasthenia gravis and implications for patient support programs.Front Public Health. 2023 May 19;11:1147489. doi: 10.3389/fpubh.2023.1147489. eCollection 2023. Front Public Health. 2023. PMID: 37275500 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical